ReviewClinical lymphoma, myeloma & leukemia2017
Waldenström Macroglobulinemia: Review of Pathogenesis and Management.
Review in Clinical lymphoma, myeloma & leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- Decoding Waldenström Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions.International journal of molecular sciences · 2026Review
- Article
- Article
- Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia.Current hematologic malignancy reports · 2024Review
- Pathophysiology and Treatments of Complications of Waldenström's Macroglobulinemia.Clinical hematology international · 2024Article
- Waldenstrom Macroglobulinemia: Clinical Presentation, Diagnosis, and Management in an Elderly Male.Cureus · 2023Article
- Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.International journal of molecular sciences · 2023Article
- Mouse models of human multiple myeloma subgroups.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Biclonal lymphoplasmacytic lymphoma/Waldenström macroglobulinemia associated with POEMS syndrome: A case report and literature review.Oncology letters · 2023Article
- The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.Clinical hematology international · 2022Review
- Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018.British journal of haematology · 2022Article
- Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression.European journal of case reports in internal medicine · 2022Article
- Monoclonal antibody-based therapies for Waldenström's macroglobulinemia.Leukemia research reports · 2022Article
- CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen.Current oncology (Toronto, Ont.) · 2021Review
- A Rare Case of Waldenstrom Macroglobulinemia of the Rectosigmoid Colon.ACG case reports journal · 2021Article
- The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer.ESMO open · 2021Review
- Cutaneous Macroglobulinosis Presenting as Serpiginous Purpura, a Case Report and Literature Review.Clinical, cosmetic and investigational dermatology · 2021Article
- Article
- Cutaneous macroglobulinosis with Waldenström macroglobulinemia.JAAD case reports · 2020Article
- Incidence, prevalence, mortality, and causes of death in Waldenström macroglobulinemia: a nationwide, population-based cohort study.BMC cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Waldenström macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M. Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis. Development of new therapies including monoclonal antibodies, proteasome inhibitors, and Bruton tyrosine kinase inhibitors have made the management of WM increasingly complex. Treatment should be tailored to the individual patient while considering many clinical factors. The clinical outcomes are expected to continue to improve, given the emergence of novel therapeutics and better understanding of the underlying pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.